SlideShare ist ein Scribd-Unternehmen logo
1 von 34
Downloaden Sie, um offline zu lesen
1
The Paediatric Committee (PDCO)
Fernando de Andres-Trelles
(UCM, PDCO, AEMPS)
www.eurordis.org
Barcelona, June 2013
2
Some of the slides based on EMA sources, gratefully
acknowledged* but opinions are personal
* Comprehensive and helpful section on “Medicines for children”
at the EMA website
http://www.ema.europa.eu/htms/human/paediatrics/introduction.
htm
3
In general, medicines are therapeutic, preventive or diagnostic
tools of chemical, biological “recombinant” or “cell” type and of
industrial origin, available on the market (with a price often
intervened) after having being authorised (“registered”) by specific
“agencies” generally at the initiative of the industry and on the
basis of data (evidence) submitted and usually generated by it
and not always easily available. They are normally prescribed and
dispensed before being used by the patient (“consumer”) who
generally does not pay directly for them. In the EU, public
institutions are the main reimbursing bodies; Pricing and
reimbursement are not related to the EMA
MEDICINES ARE COMPLEX
4
In Normal Conditions of Use, meaning:
Summary of Product Characteristics (SPC)
Patient Leaflet (PL)
Packaging
Quality
Safety
Efficacy
Medicines evaluation for registration
And, if centralised, European Public
Assessment Report (EPAR)
MEDICINES ARE REGISTERED AS SUCH
5
European Medicines Agency (EMA). Established 1995
In a way, it is a “virtual
agency”. It depends on/
interacts with 27+2 National
Agencies. Many drug related
issues never reach the EMA
e.g. some less
innovative drugs,
therapeutic value,
reimbursement
matters
Or
pricing…
The Paediatric Investigation Plans
(PIPS) are always dealt with by the
PDCO at the EMEA even for
products using national or
decentralized procedures
6
The Regulatory process in the EU now incorporates
a specific step to consider paediatric plans on time
Orphan Drug Designation (COMP)
(Optional request)
Scientific Advice/Protocol Assistance (SAWP). Optional prospective case
by case request. Not binding advice. Free of charge for paediatric plans
and for orphan drugs
IIII IINon-clinicalPharm
(CHMP)
Approves ALL
centralized hu-
man medicines
Binding decision
Clinical development
Post-mkt
PIP
(PDCO prospectively decides
what to inves-tigate for
children CASE BY CASE).
Compulsory request. Binding
decision
7
SAWP
CHMP
(Committee for Human Medicinal Products)
COMP
(Committee for Orphan Medicinal Products)
HMPC
(Committee for Herbal Medicinal Products)
PDCO
(Paediatric Committee)
Chair: D. Brasseur - Vice-Chair: D. Mentzer
29 members nominated by NA
and 3+3 patients and health profesionals representatives
CAT
(Committee for Advanced Therapy Medicinal Products)
PRAC
(Pharmacovigilance Risk Assessment Committee)
EMA “human” committees basically nominated by National Agencies (in
chronological order) and one working party of the CHMP –the SAWP
(scientific advice working party)-
With input from
PDCO and COMP
8
The situation before the Regulation
• 20% of the EU population, i.e. 100 million, is aged less than 16
years
– premature neonate, term neonate, infant, child,
adolescent
• 50-90% of paediatric medicines have not been tested and
evaluated
• US paediatric data (BPCA) not submitted to EU Agencies
Potential Risks:
- adverse effects (overdosing)
- inefficacy (under-dosing)
- improper formulation
- delay in access to innovative medicines
9
No much improvement in the first 12 years of the
European Medicines Agency
33%
42%
25%
Paediatric
indication
Potential
paediatric
indication
Not applicable
258 active moieties approved (1995- January 2006) through EMA
10
There is significant lack of knowledge on many aspects of
medicines for pediatric populations that cannot be easily
extrapolated from adult data. A simple illustration…
MEDICINES FOR CHILDREN
11
Pharmacokinetics (PK) change with age in a
non-linear way
Half-life of diazepam
(hours)
Premature
neonates
Neonates
Infants
Children
Adults
age
0-30
days
1-24
months
2-8
years
25-45
years
(60)
(40)
(20)
Paediatric ages (ICH)
•Preterm newborn infants
•Term newborn infants (0 to 27 days)
•Infants and toddlers (28 days to 23 months)
•Children (2 to 11 years)
•2 to 5 years (~ “pre school”)
•5 to 11 years (~ “school age”)
•Adolescents (12 to 17 years)
12
Two examples from the Summary of Product
Characteristics of medicines developed prior to
the Paediatric Regulation, one used for multiple
sclerosis (MS) and the other for hemophilia
13
4.1 Therapeutic indications
** is indicated for the treatment of
• Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials,
this was characterised by two or more acute exacerbations (relapses) in
the previous three years without evidence of continuous progression
between relapses; ** slows the progression of disability and decreases
the frequency of relapses.
• Patients with a single demyelinating event with an active inflammatory
process, if it is severe enough to warrant treatment with intravenous
corticosteroids, if alternative diagnoses have been excluded, and if they
are determined to be at high risk of developing clinically definite
multiple sclerosis (see section 5.1). ** should be discontinued in patients
who develop progressive MS.
SPC of a drug for Multiple Sclerosis “standard ” in
paediatric therapeutics: interferon beta-1a (**) (1)
No mention of paediatric patients
14
4.2 Posology and method of administration
……
Adults: The recommended dosage for the treatment of relapsing MS
is 30 micrograms (1 ml solution), administered by intramuscular (IM)
injection once a week (see section 6.6). No additional benefit
has been shown by administering a higher dose (60 micrograms)
once a week.
Paediatric population: The safety and efficacy of ** in adolescents
aged 12 to 16 years have not yet been established. Currently
available data are described in section 4.8 and 5.1 but
no recommendation on a posology can be made. The safety and
efficacy of ** in children below 12 years of age have not yet been
established. No data are available
SPC of a drug for Multiple Sclerosis “standard ” in
paediatric therapeutics: interferon beta-1a (**) (2)
15
5.1 Pharmacodynamic properties
Pharmacotherapeutic Group: Interferons, ATC code: L03
AB07. Interferons are a family of naturally occurring proteins …..,
Paediatric population: Limited data of the efficacy/safety of ** 15
micrograms IM once per week (n=8) as compared to no treatment
(n=8) with follow up for 4 years showed results in line to those seen
in adults, although the EDSS scores increased in the treated group
over the 4 year follow-up thus indicating disease progression. No
direct comparison with the dose currently recommended in adults is
available.
SPC of a drug for Multiple Sclerosis “standard ” in
paediatric therapeutics: interferon beta-1a (**) (3)
16
4.8 Undesirable effects
…….
…….
…….
Paediatric population: Limited published data suggest that the
safety profile in adolescents from 12 to 16 years of age receiving
** 30 micrograms IM once per week is similar to that seen in
adults.
SPC of a drug for Multiple Sclerosis “standard ” in
paediatric therapeutics: interferon beta-1a (**) (4)
17
4.1 Therapeutic indications
…….
Paediatric population
The safety and efficacy of *** in children less than 6 years of age
has not been established. There are insufficient data to recommend
the use of *** in children less than 6 years of age.
…….
5.1 Pharmacodynamic properties
There are insufficient data to recommend the use of *** in children
less than 6 years of age
……..
Current Summary of the Product Characteristics of a
factor IX (***): Use in children hardly mentioned:
18
Registration: What if it is not profitable to
register/develop drugs or generate data to meet
health needs?
• One approach is to ensure that the required medicinal
products become profitable to the sponsors. There are two
main examples in the EU :
 Orphan drugs (EU regulation in since 2000)
 Drugs for pediatric populations (the pediatric regulation
(Regulation -EC- No 1901/2006 + 1902/2006) came into force
on the 26 January 2007
• Another is for the public institutions to take the initiative and
do it themselves. This is also a possibility in the pediatric
regulation
orphan diseases, medicines for children, diseases of poverty…
19
The Regulation on Paediatric Medicines (Regulation -EC- No
1901/2006 + 1902/2006 ), to stimulate much-needed research,
came into force on January 26, 2007.
A new EMA committee (PDCO) met for the first time on July 2007.
The PDCO meets monthly at the EMA and is responsible for
coordinating/implementing all aspects of the Regulation
The 1000th PIP was submitted in October 2010
20
The stated objectives of the Regulation
• Improve the health of children
 Increase high quality, ethical research into medicines
for children
 Increase availability of authorised medicines for
children
 Increase information on medicines
• Achieve the above
 Without unnecessary studies in children
 Without delaying authorisation for adults
21
The main tools to achieve these objectives
• An expert committee:
Paediatric Committee (PDCO)
• A binding (agreed, evolving) paediatric development: the
Paediatric Investigation Plan (PIP)
• A set of rewards and incentives
 For new and on-patent products
 For off-patent products
• A series of other tools for information, transparency, and
stimulation of research
22
The Pediatric Committee (PDCO)
23
The Paediatric Regulation combines obligations and
incentives/rewards (1)
They depend on whether the medicine…
Is under development (art 7)
Compulsory to submit a PIP
Incentive of 6 month extension data protection
Is on the market but still under data protection (art 8)
If (usually optional) PIP submitted
Reward of 6 month extension data protection
Is on the market without protection (art 30)
If developed for children according to a PIP
Paediatric Use Marketing Authorisation (PUMA) granted
Is an orphan medicine (art 37)
Compulsory, if under development, to submit a PIP
Incentive of 2 extra years of market exclusivity
24
A Paediatric Investigation Plan (PIP) pre-approved by the Paediatric
Committee (PDCO) is always needed for the reward
It must be submitted to the PDCO early in the development for
adults (end of phase I). A deferral of its implementation can be
agreed, A waiver is granted in some circumstances (e.g. adult only
disease, lack of expected significant benefit, etc.)
The reward may be obtained if the PIP is implemented, even,
possibly, in cases where the results, once obtained, do not lead to
any indications.
The Paediatric Regulation combines obligations and
incentives/rewards (2)
25
• Is the basis for the development and authorisation of a medicinal
product for the paediatric population subsets
• Includes details of the timing and the measures proposed to
demonstrate:
 Quality
 Safety
 Efficacy
 As well as prospective pharmacovigilance measures (e.g.
risk management plans including for long-term effects)
• Is to be agreed upon and/or amended by the Paediatric
Committee (PDCO)
• Is binding! on Company
The Pediatric Investigation Plan (PIP):
Marketing
Authorisation
criteria
26
Paediatric clinical development (when?)
• Mainly or exclusively paediatric diseases: Complete
development in children. Initial tolerability/ safety in adults.
• Serious diseases with limited therapeutic options both in
adults and children: early development in children.
• Other diseases: development in children only when development
in adults well advanced. Even, for safety reasons, post-marketing
of the adult medicine.
27
1
Non-clin Phase 1 Phase 2 Phase 3 Post approval
Paed. Investig. Plan
Compliance
Deferral (annual
report on
progress)
Waiver
MA
Amendments
Paediatric Committee
Scientific Advice
Working Party
EU Scientific advice
CHMP
NCA
Presentación de PIP: cuándo
(Meds no autorizados)
Submission of the PIP (when?)
28
• Inventory of paediatric needs, based on survey of existing uses by
Member States (MS).
 EU funding available for research, esp. for off patent products identified as
priority
• Critical assessment of available results of paediatric studies, to be
submitted by Companies to Member States or the EMA (arts 45 and
46)
• Improved communication and transparency of paediatric information
e.g.
 SPC to refer to children studies even if results negative.
 Paediatric clinical trials to be published in EUCTR (EU Clinical Trials Register)
 Approved PIPs are accessible on the EMA webpage
• European network of paediatric research to be coordinated by the
EMA-PDCO.
Other measures established by the Regulation (normally with
input/ coordination by the PDCO)
29
Some consequences and issues…
Companies cannot claim any longer that they are not
interested in studying a certain indication for paediatric
subjects. If the PDCO finds it of benefit for children, they are
obliged to do so
Without unnecessary studies in children
Without delaying authorization in adults
And this often requires performing clinical studies in children . . .
30
• International ethics principles: Declaration of Helsinki (Endorsed
generally by European countries, but not fully by the U.S. FDA -
mainly on placebo related issues-), etc.
• EU Directive on Clinical Trials: 2001/20/EC
• Commission Directive on Good Clinical Practice: 2005/28/EC
• EU Ethical Considerations on clinical trials with children
(recommendation by an ad hoc group chaired by the European
Commission. Final: 2008)
Obviously, ethics is a major issue for paediatric clinical trials
…. But there is a lack of full harmonization even within the
European Union,
e.g. some Member States do not allow conducting any paediatric
clinical trials without potential direct clinical benefit for the
participants
There is guidance/ legislation on the matter ….
31
Sometimes it is not easy to distinguish between what it is an
“adult only” indication or a “condition” occurring both in adults
and children,
eg. a drug may be being developed in adults for an adult
cancer. What if there is reason to believe that its mechanism
of action would apply equally well to some exclusively
paediatric cancers?
When felt useful, a paediatric development is, at least,
“encouraged”
Some consequences and issues…
32
As so many new drugs are simultaneously investigated, the
availability of subjects for clinical trials becomes limited, especially
for less prevalent conditions…
How many 13-15 y.o. schizophrenia patients can
feasibly be enrolled in a c.t.?
In a placebo controlled c.t.?
According to ethical principles?
The PDCO tries to prioritise according to perceived drug
expectations and health needs
Wider use should be done of alternative methods of
generating evidence
Some consequences and issues…
33
What about PIPs for new medicines for our previous example:
Multiple Sclerosis (MS)? Data as for January 2012
Since 2007, 17 applications for PIP/ Waiver for products
related to Multiple Sclerosis submitted:
Art. 7: 14
Art. 8: 2
Art.30 (PUMA): 1
11 with published Decisions:
8 agreed PIPs
3 full waivers
But still no related new paediatric
indication for MS granted
34
The new regulation aims to improve the situation of medicines for
paediatric populations, including for orphan diseases. It will
generate abundant research, bureaucracy and rewards for the
industries.
That this is, in fact, efficiently translated into relevant health benefits
for children is a shared responsibility that requires transparency
and good coordination between all the involved parties and should
evolve under public scrutiny.
At least the beginning looks promising
Conclusion

Weitere ähnliche Inhalte

Was ist angesagt?

Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
US FDA Regulatory Submissions
US FDA Regulatory SubmissionsUS FDA Regulatory Submissions
US FDA Regulatory SubmissionsChandra Mohan
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureOffice of Health Economics
 
CTD ~ Common Technical Document
CTD ~ Common Technical DocumentCTD ~ Common Technical Document
CTD ~ Common Technical DocumentGuru Balaji .S
 
Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Prakash Ghimire
 
Regulatory dossier preparation and submission as per CTD format
Regulatory dossier preparation and submission as per CTD formatRegulatory dossier preparation and submission as per CTD format
Regulatory dossier preparation and submission as per CTD formatAvinash sharma
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in euRajaniKarpur
 
European medicines agency
European medicines agencyEuropean medicines agency
European medicines agencyVicky Vignesh
 
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxGLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxSanthiNori1
 
Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards Rumel Dey
 
Comparative Study of Dossier Compilation & Submission Process of Drug Product...
Comparative Study of Dossier Compilation & Submission Process of Drug Product...Comparative Study of Dossier Compilation & Submission Process of Drug Product...
Comparative Study of Dossier Compilation & Submission Process of Drug Product...DeveshDRA
 
Medical device clinical evaluation
Medical device clinical evaluationMedical device clinical evaluation
Medical device clinical evaluationMalesh M
 
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN Arul Packiadhas
 
Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India RichaTrivedi16
 

Was ist angesagt? (20)

Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
US FDA Regulatory Submissions
US FDA Regulatory SubmissionsUS FDA Regulatory Submissions
US FDA Regulatory Submissions
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised Procedure
 
CTD Guidelines Overview
CTD Guidelines OverviewCTD Guidelines Overview
CTD Guidelines Overview
 
CTD ~ Common Technical Document
CTD ~ Common Technical DocumentCTD ~ Common Technical Document
CTD ~ Common Technical Document
 
Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)
 
Japanese regulatory affairs
Japanese regulatory affairsJapanese regulatory affairs
Japanese regulatory affairs
 
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh AlemiPharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
 
Regulatory dossier preparation and submission as per CTD format
Regulatory dossier preparation and submission as per CTD formatRegulatory dossier preparation and submission as per CTD format
Regulatory dossier preparation and submission as per CTD format
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
 
European medicines agency
European medicines agencyEuropean medicines agency
European medicines agency
 
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxGLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
 
Post approval of drugs
Post approval of drugsPost approval of drugs
Post approval of drugs
 
Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards
 
Comparative Study of Dossier Compilation & Submission Process of Drug Product...
Comparative Study of Dossier Compilation & Submission Process of Drug Product...Comparative Study of Dossier Compilation & Submission Process of Drug Product...
Comparative Study of Dossier Compilation & Submission Process of Drug Product...
 
Medical device clinical evaluation
Medical device clinical evaluationMedical device clinical evaluation
Medical device clinical evaluation
 
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
 
The essential changes in the new pbrer format
The essential changes in the new pbrer formatThe essential changes in the new pbrer format
The essential changes in the new pbrer format
 
Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India
 

Ähnlich wie Paediatric committee

Pediatric Clinical Pharmacology
Pediatric Clinical PharmacologyPediatric Clinical Pharmacology
Pediatric Clinical PharmacologyDang Thanh Tuan
 
Tomato Flu ( Pooja R. Mundhe)
Tomato Flu ( Pooja R. Mundhe) Tomato Flu ( Pooja R. Mundhe)
Tomato Flu ( Pooja R. Mundhe) PoojaMundhe11
 
Neonate drug utilization
Neonate drug utilizationNeonate drug utilization
Neonate drug utilizationSarah Beatriz
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance OverviewSivasankaranV
 
(마더세이프라운드) 43차 유럽기형학회 강의
(마더세이프라운드)  43차 유럽기형학회 강의(마더세이프라운드)  43차 유럽기형학회 강의
(마더세이프라운드) 43차 유럽기형학회 강의mothersafe
 
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To..."Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...Vall d'Hebron Institute of Research (VHIR)
 
Adverse Drug Reaction Monitoring.pdf
Adverse Drug Reaction Monitoring.pdfAdverse Drug Reaction Monitoring.pdf
Adverse Drug Reaction Monitoring.pdfLaurie Smith
 
Etica 04 medicines for children licensed by the european agency
Etica 04   medicines for children licensed by the european agencyEtica 04   medicines for children licensed by the european agency
Etica 04 medicines for children licensed by the european agencygisa_legal
 
éTica 04 medicines for children licensed by the european agency
éTica 04   medicines for children licensed by the european agencyéTica 04   medicines for children licensed by the european agency
éTica 04 medicines for children licensed by the european agencygisa_legal
 
Pharmacovigilance - an introduction
Pharmacovigilance - an introductionPharmacovigilance - an introduction
Pharmacovigilance - an introductionBharti kumari
 
Concept of essential medicines and rational use of medicines
Concept of essential medicines and rational use of medicinesConcept of essential medicines and rational use of medicines
Concept of essential medicines and rational use of medicinesVivek Nayak
 
Pharmacovigilance reporting methods
Pharmacovigilance  reporting methodsPharmacovigilance  reporting methods
Pharmacovigilance reporting methodsArchana Gawade
 
Pediatric Primary Care In Europe. The most appropriate medical professional ...
Pediatric Primary Care In Europe.  The most appropriate medical professional ...Pediatric Primary Care In Europe.  The most appropriate medical professional ...
Pediatric Primary Care In Europe. The most appropriate medical professional ...pediatricworld MSN
 

Ähnlich wie Paediatric committee (20)

Pediatric Clinical Pharmacology
Pediatric Clinical PharmacologyPediatric Clinical Pharmacology
Pediatric Clinical Pharmacology
 
Tomato Flu ( Pooja R. Mundhe)
Tomato Flu ( Pooja R. Mundhe) Tomato Flu ( Pooja R. Mundhe)
Tomato Flu ( Pooja R. Mundhe)
 
Pharmacovigilance: A review
Pharmacovigilance: A reviewPharmacovigilance: A review
Pharmacovigilance: A review
 
Neonate drug utilization
Neonate drug utilizationNeonate drug utilization
Neonate drug utilization
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance Overview
 
(마더세이프라운드) 43차 유럽기형학회 강의
(마더세이프라운드)  43차 유럽기형학회 강의(마더세이프라운드)  43차 유럽기형학회 강의
(마더세이프라운드) 43차 유럽기형학회 강의
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To..."Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
 
Adverse Drug Reaction Monitoring.pdf
Adverse Drug Reaction Monitoring.pdfAdverse Drug Reaction Monitoring.pdf
Adverse Drug Reaction Monitoring.pdf
 
Etica 04 medicines for children licensed by the european agency
Etica 04   medicines for children licensed by the european agencyEtica 04   medicines for children licensed by the european agency
Etica 04 medicines for children licensed by the european agency
 
éTica 04 medicines for children licensed by the european agency
éTica 04   medicines for children licensed by the european agencyéTica 04   medicines for children licensed by the european agency
éTica 04 medicines for children licensed by the european agency
 
Pharmacovigilance - an introduction
Pharmacovigilance - an introductionPharmacovigilance - an introduction
Pharmacovigilance - an introduction
 
Concept of essential medicines and rational use of medicines
Concept of essential medicines and rational use of medicinesConcept of essential medicines and rational use of medicines
Concept of essential medicines and rational use of medicines
 
ICH E11.pptx
ICH E11.pptxICH E11.pptx
ICH E11.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Pharmacoepidemiology
Pharmacoepidemiology Pharmacoepidemiology
Pharmacoepidemiology
 
Pharmacovigilance reporting methods
Pharmacovigilance  reporting methodsPharmacovigilance  reporting methods
Pharmacovigilance reporting methods
 
Pediatric Primary Care In Europe. The most appropriate medical professional ...
Pediatric Primary Care In Europe.  The most appropriate medical professional ...Pediatric Primary Care In Europe.  The most appropriate medical professional ...
Pediatric Primary Care In Europe. The most appropriate medical professional ...
 
Pharmacovigilence
PharmacovigilencePharmacovigilence
Pharmacovigilence
 
Pharmacovigilence
PharmacovigilencePharmacovigilence
Pharmacovigilence
 

Mehr von EURORDIS Rare Diseases Europe (20)

Gene editing to treat cystic fibrosis_Vertex
Gene editing to treat cystic fibrosis_VertexGene editing to treat cystic fibrosis_Vertex
Gene editing to treat cystic fibrosis_Vertex
 
From Laboratory to Patient
From Laboratory to PatientFrom Laboratory to Patient
From Laboratory to Patient
 
Committee for Advanced Therapies
Committee for Advanced TherapiesCommittee for Advanced Therapies
Committee for Advanced Therapies
 
3b. Introductory Statistics - Julia Saperia
3b. Introductory Statistics - Julia Saperia3b. Introductory Statistics - Julia Saperia
3b. Introductory Statistics - Julia Saperia
 
3.nf
3.nf3.nf
3.nf
 
3.i
3.i3.i
3.i
 
2.it
2.it2.it
2.it
 
2.ab
2.ab2.ab
2.ab
 
1.3 df
1.3 df1.3 df
1.3 df
 
1.4 av
1.4 av1.4 av
1.4 av
 
2.it
2.it2.it
2.it
 
2.ab
2.ab2.ab
2.ab
 
1.2 fpr
1.2 fpr1.2 fpr
1.2 fpr
 
1.1 annaritamiccio
1.1 annaritamiccio1.1 annaritamiccio
1.1 annaritamiccio
 
1 engaging with ema methodology and support
1 engaging with ema methodology and support1 engaging with ema methodology and support
1 engaging with ema methodology and support
 
panorama of actions patient organisations
 panorama of actions patient organisations panorama of actions patient organisations
panorama of actions patient organisations
 
Chmp 2018 houyez
Chmp 2018 houyezChmp 2018 houyez
Chmp 2018 houyez
 
Cup case study
Cup case studyCup case study
Cup case study
 
Hta fhz
Hta fhzHta fhz
Hta fhz
 
Patients chmp 2018
Patients chmp 2018Patients chmp 2018
Patients chmp 2018
 

Kürzlich hochgeladen

Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxEduSkills OECD
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphNetziValdelomar1
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 

Kürzlich hochgeladen (20)

Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a Paragraph
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 

Paediatric committee

  • 1. 1 The Paediatric Committee (PDCO) Fernando de Andres-Trelles (UCM, PDCO, AEMPS) www.eurordis.org Barcelona, June 2013
  • 2. 2 Some of the slides based on EMA sources, gratefully acknowledged* but opinions are personal * Comprehensive and helpful section on “Medicines for children” at the EMA website http://www.ema.europa.eu/htms/human/paediatrics/introduction. htm
  • 3. 3 In general, medicines are therapeutic, preventive or diagnostic tools of chemical, biological “recombinant” or “cell” type and of industrial origin, available on the market (with a price often intervened) after having being authorised (“registered”) by specific “agencies” generally at the initiative of the industry and on the basis of data (evidence) submitted and usually generated by it and not always easily available. They are normally prescribed and dispensed before being used by the patient (“consumer”) who generally does not pay directly for them. In the EU, public institutions are the main reimbursing bodies; Pricing and reimbursement are not related to the EMA MEDICINES ARE COMPLEX
  • 4. 4 In Normal Conditions of Use, meaning: Summary of Product Characteristics (SPC) Patient Leaflet (PL) Packaging Quality Safety Efficacy Medicines evaluation for registration And, if centralised, European Public Assessment Report (EPAR) MEDICINES ARE REGISTERED AS SUCH
  • 5. 5 European Medicines Agency (EMA). Established 1995 In a way, it is a “virtual agency”. It depends on/ interacts with 27+2 National Agencies. Many drug related issues never reach the EMA e.g. some less innovative drugs, therapeutic value, reimbursement matters Or pricing… The Paediatric Investigation Plans (PIPS) are always dealt with by the PDCO at the EMEA even for products using national or decentralized procedures
  • 6. 6 The Regulatory process in the EU now incorporates a specific step to consider paediatric plans on time Orphan Drug Designation (COMP) (Optional request) Scientific Advice/Protocol Assistance (SAWP). Optional prospective case by case request. Not binding advice. Free of charge for paediatric plans and for orphan drugs IIII IINon-clinicalPharm (CHMP) Approves ALL centralized hu- man medicines Binding decision Clinical development Post-mkt PIP (PDCO prospectively decides what to inves-tigate for children CASE BY CASE). Compulsory request. Binding decision
  • 7. 7 SAWP CHMP (Committee for Human Medicinal Products) COMP (Committee for Orphan Medicinal Products) HMPC (Committee for Herbal Medicinal Products) PDCO (Paediatric Committee) Chair: D. Brasseur - Vice-Chair: D. Mentzer 29 members nominated by NA and 3+3 patients and health profesionals representatives CAT (Committee for Advanced Therapy Medicinal Products) PRAC (Pharmacovigilance Risk Assessment Committee) EMA “human” committees basically nominated by National Agencies (in chronological order) and one working party of the CHMP –the SAWP (scientific advice working party)- With input from PDCO and COMP
  • 8. 8 The situation before the Regulation • 20% of the EU population, i.e. 100 million, is aged less than 16 years – premature neonate, term neonate, infant, child, adolescent • 50-90% of paediatric medicines have not been tested and evaluated • US paediatric data (BPCA) not submitted to EU Agencies Potential Risks: - adverse effects (overdosing) - inefficacy (under-dosing) - improper formulation - delay in access to innovative medicines
  • 9. 9 No much improvement in the first 12 years of the European Medicines Agency 33% 42% 25% Paediatric indication Potential paediatric indication Not applicable 258 active moieties approved (1995- January 2006) through EMA
  • 10. 10 There is significant lack of knowledge on many aspects of medicines for pediatric populations that cannot be easily extrapolated from adult data. A simple illustration… MEDICINES FOR CHILDREN
  • 11. 11 Pharmacokinetics (PK) change with age in a non-linear way Half-life of diazepam (hours) Premature neonates Neonates Infants Children Adults age 0-30 days 1-24 months 2-8 years 25-45 years (60) (40) (20) Paediatric ages (ICH) •Preterm newborn infants •Term newborn infants (0 to 27 days) •Infants and toddlers (28 days to 23 months) •Children (2 to 11 years) •2 to 5 years (~ “pre school”) •5 to 11 years (~ “school age”) •Adolescents (12 to 17 years)
  • 12. 12 Two examples from the Summary of Product Characteristics of medicines developed prior to the Paediatric Regulation, one used for multiple sclerosis (MS) and the other for hemophilia
  • 13. 13 4.1 Therapeutic indications ** is indicated for the treatment of • Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; ** slows the progression of disability and decreases the frequency of relapses. • Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1). ** should be discontinued in patients who develop progressive MS. SPC of a drug for Multiple Sclerosis “standard ” in paediatric therapeutics: interferon beta-1a (**) (1) No mention of paediatric patients
  • 14. 14 4.2 Posology and method of administration …… Adults: The recommended dosage for the treatment of relapsing MS is 30 micrograms (1 ml solution), administered by intramuscular (IM) injection once a week (see section 6.6). No additional benefit has been shown by administering a higher dose (60 micrograms) once a week. Paediatric population: The safety and efficacy of ** in adolescents aged 12 to 16 years have not yet been established. Currently available data are described in section 4.8 and 5.1 but no recommendation on a posology can be made. The safety and efficacy of ** in children below 12 years of age have not yet been established. No data are available SPC of a drug for Multiple Sclerosis “standard ” in paediatric therapeutics: interferon beta-1a (**) (2)
  • 15. 15 5.1 Pharmacodynamic properties Pharmacotherapeutic Group: Interferons, ATC code: L03 AB07. Interferons are a family of naturally occurring proteins ….., Paediatric population: Limited data of the efficacy/safety of ** 15 micrograms IM once per week (n=8) as compared to no treatment (n=8) with follow up for 4 years showed results in line to those seen in adults, although the EDSS scores increased in the treated group over the 4 year follow-up thus indicating disease progression. No direct comparison with the dose currently recommended in adults is available. SPC of a drug for Multiple Sclerosis “standard ” in paediatric therapeutics: interferon beta-1a (**) (3)
  • 16. 16 4.8 Undesirable effects ……. ……. ……. Paediatric population: Limited published data suggest that the safety profile in adolescents from 12 to 16 years of age receiving ** 30 micrograms IM once per week is similar to that seen in adults. SPC of a drug for Multiple Sclerosis “standard ” in paediatric therapeutics: interferon beta-1a (**) (4)
  • 17. 17 4.1 Therapeutic indications ……. Paediatric population The safety and efficacy of *** in children less than 6 years of age has not been established. There are insufficient data to recommend the use of *** in children less than 6 years of age. ……. 5.1 Pharmacodynamic properties There are insufficient data to recommend the use of *** in children less than 6 years of age …….. Current Summary of the Product Characteristics of a factor IX (***): Use in children hardly mentioned:
  • 18. 18 Registration: What if it is not profitable to register/develop drugs or generate data to meet health needs? • One approach is to ensure that the required medicinal products become profitable to the sponsors. There are two main examples in the EU :  Orphan drugs (EU regulation in since 2000)  Drugs for pediatric populations (the pediatric regulation (Regulation -EC- No 1901/2006 + 1902/2006) came into force on the 26 January 2007 • Another is for the public institutions to take the initiative and do it themselves. This is also a possibility in the pediatric regulation orphan diseases, medicines for children, diseases of poverty…
  • 19. 19 The Regulation on Paediatric Medicines (Regulation -EC- No 1901/2006 + 1902/2006 ), to stimulate much-needed research, came into force on January 26, 2007. A new EMA committee (PDCO) met for the first time on July 2007. The PDCO meets monthly at the EMA and is responsible for coordinating/implementing all aspects of the Regulation The 1000th PIP was submitted in October 2010
  • 20. 20 The stated objectives of the Regulation • Improve the health of children  Increase high quality, ethical research into medicines for children  Increase availability of authorised medicines for children  Increase information on medicines • Achieve the above  Without unnecessary studies in children  Without delaying authorisation for adults
  • 21. 21 The main tools to achieve these objectives • An expert committee: Paediatric Committee (PDCO) • A binding (agreed, evolving) paediatric development: the Paediatric Investigation Plan (PIP) • A set of rewards and incentives  For new and on-patent products  For off-patent products • A series of other tools for information, transparency, and stimulation of research
  • 23. 23 The Paediatric Regulation combines obligations and incentives/rewards (1) They depend on whether the medicine… Is under development (art 7) Compulsory to submit a PIP Incentive of 6 month extension data protection Is on the market but still under data protection (art 8) If (usually optional) PIP submitted Reward of 6 month extension data protection Is on the market without protection (art 30) If developed for children according to a PIP Paediatric Use Marketing Authorisation (PUMA) granted Is an orphan medicine (art 37) Compulsory, if under development, to submit a PIP Incentive of 2 extra years of market exclusivity
  • 24. 24 A Paediatric Investigation Plan (PIP) pre-approved by the Paediatric Committee (PDCO) is always needed for the reward It must be submitted to the PDCO early in the development for adults (end of phase I). A deferral of its implementation can be agreed, A waiver is granted in some circumstances (e.g. adult only disease, lack of expected significant benefit, etc.) The reward may be obtained if the PIP is implemented, even, possibly, in cases where the results, once obtained, do not lead to any indications. The Paediatric Regulation combines obligations and incentives/rewards (2)
  • 25. 25 • Is the basis for the development and authorisation of a medicinal product for the paediatric population subsets • Includes details of the timing and the measures proposed to demonstrate:  Quality  Safety  Efficacy  As well as prospective pharmacovigilance measures (e.g. risk management plans including for long-term effects) • Is to be agreed upon and/or amended by the Paediatric Committee (PDCO) • Is binding! on Company The Pediatric Investigation Plan (PIP): Marketing Authorisation criteria
  • 26. 26 Paediatric clinical development (when?) • Mainly or exclusively paediatric diseases: Complete development in children. Initial tolerability/ safety in adults. • Serious diseases with limited therapeutic options both in adults and children: early development in children. • Other diseases: development in children only when development in adults well advanced. Even, for safety reasons, post-marketing of the adult medicine.
  • 27. 27 1 Non-clin Phase 1 Phase 2 Phase 3 Post approval Paed. Investig. Plan Compliance Deferral (annual report on progress) Waiver MA Amendments Paediatric Committee Scientific Advice Working Party EU Scientific advice CHMP NCA Presentación de PIP: cuándo (Meds no autorizados) Submission of the PIP (when?)
  • 28. 28 • Inventory of paediatric needs, based on survey of existing uses by Member States (MS).  EU funding available for research, esp. for off patent products identified as priority • Critical assessment of available results of paediatric studies, to be submitted by Companies to Member States or the EMA (arts 45 and 46) • Improved communication and transparency of paediatric information e.g.  SPC to refer to children studies even if results negative.  Paediatric clinical trials to be published in EUCTR (EU Clinical Trials Register)  Approved PIPs are accessible on the EMA webpage • European network of paediatric research to be coordinated by the EMA-PDCO. Other measures established by the Regulation (normally with input/ coordination by the PDCO)
  • 29. 29 Some consequences and issues… Companies cannot claim any longer that they are not interested in studying a certain indication for paediatric subjects. If the PDCO finds it of benefit for children, they are obliged to do so Without unnecessary studies in children Without delaying authorization in adults And this often requires performing clinical studies in children . . .
  • 30. 30 • International ethics principles: Declaration of Helsinki (Endorsed generally by European countries, but not fully by the U.S. FDA - mainly on placebo related issues-), etc. • EU Directive on Clinical Trials: 2001/20/EC • Commission Directive on Good Clinical Practice: 2005/28/EC • EU Ethical Considerations on clinical trials with children (recommendation by an ad hoc group chaired by the European Commission. Final: 2008) Obviously, ethics is a major issue for paediatric clinical trials …. But there is a lack of full harmonization even within the European Union, e.g. some Member States do not allow conducting any paediatric clinical trials without potential direct clinical benefit for the participants There is guidance/ legislation on the matter ….
  • 31. 31 Sometimes it is not easy to distinguish between what it is an “adult only” indication or a “condition” occurring both in adults and children, eg. a drug may be being developed in adults for an adult cancer. What if there is reason to believe that its mechanism of action would apply equally well to some exclusively paediatric cancers? When felt useful, a paediatric development is, at least, “encouraged” Some consequences and issues…
  • 32. 32 As so many new drugs are simultaneously investigated, the availability of subjects for clinical trials becomes limited, especially for less prevalent conditions… How many 13-15 y.o. schizophrenia patients can feasibly be enrolled in a c.t.? In a placebo controlled c.t.? According to ethical principles? The PDCO tries to prioritise according to perceived drug expectations and health needs Wider use should be done of alternative methods of generating evidence Some consequences and issues…
  • 33. 33 What about PIPs for new medicines for our previous example: Multiple Sclerosis (MS)? Data as for January 2012 Since 2007, 17 applications for PIP/ Waiver for products related to Multiple Sclerosis submitted: Art. 7: 14 Art. 8: 2 Art.30 (PUMA): 1 11 with published Decisions: 8 agreed PIPs 3 full waivers But still no related new paediatric indication for MS granted
  • 34. 34 The new regulation aims to improve the situation of medicines for paediatric populations, including for orphan diseases. It will generate abundant research, bureaucracy and rewards for the industries. That this is, in fact, efficiently translated into relevant health benefits for children is a shared responsibility that requires transparency and good coordination between all the involved parties and should evolve under public scrutiny. At least the beginning looks promising Conclusion